ArticleOman medical journal2025
Differences in HRQOL among Children with SCD Who Received Hydroxyurea and Those Who Did Not: A Quantitative Comparison Study.
Article in Oman medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Hydroxyurea is been recommended for patients with sickle cell disease (SCD) as it reduces the complications from the disease by increasing the production of fetal hemoglobin. In Oman, hydroxyurea is not consistently prescribed to children with SCD, and limited research has compared the health-related quality of life (HRQOL) among children prescribed hydroxyurea. Thus, this study evaluated HRQOL differences between children with SCD who received hydroxyurea and those who did not. Methods: A cross-sectional study was conducted on children from a hematology clinic at a tertiary hospital in Oman. We collected the data using two questionnaires: HRQOL-SCD and HRQOL-Generic. A one-way analysis of variance was used for statistical analysis. Results: A total of 74 children (47.3% male and 52.7% female) completed the questionnaire; 33 children were on hydroxyurea and 41 were not. A significant difference in HRQOL scores was found between children receiving hydroxyurea and those not taking the drug [F (1,68) = 419.4; p-value = 0.001]. Regression analysis revealed that hydroxyurea was a significant predictor of improved HRQOL among children with SCD. An R2 of 0.87 indicated that 87.0% of the variability in the child-reported HRQOL-Generic was explained by parental familiarity, self-efficacy, child age, sex, and receiving hydroxyurea [R2 = 0.87, F (8,69) = 52.4; p-value < 0.001]. Conclusions: Hydroxyurea improved the children's HRQOL compared to those who did not receive the drug. These findings support the use of hydroxyurea in children to improve HRQOL and reduce vaso-occlusive episodes. We recommend increasing parents' understanding of hydroxyurea's significance and devising strategies to promote children's medication adherence. It is essential to modify the SCD management protocol to optimize the HRQOL among children with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.